Inhibition of p38 mitogen-activated protein kinase down-regulates the inflammatory osteolysis response to titanium particles in a murine osteolysis model

Inflammation

Volumn 35, Issue 6, 2012, Pages 1798-1806

  Chen, Desheng ^a,b   Guo, Yongyuan ^a   Mao, Xin ^a   Zhang, Xianlong ^a  

^a SHANGHAI JIAO TONG UNIVERSITY   (China)

^b NINGXIA MEDICAL UNIVERSITY   (China)

Author keywords

Inflammatory; Osteolysis; P38 mitogen activated protein kinase; Ti particles

Indexed keywords

4 (4 FLUOROPHENYL) 2 (4 METHYLSULFINYLPHENYL) 5 (4 PYRIDYL)IMIDAZOLE; ACID PHOSPHATASE TARTRATE RESISTANT ISOENZYME; GELATINASE B; MITOGEN ACTIVATED PROTEIN KINASE P38; TARTARIC ACID; TITANIUM; TUMOR NECROSIS FACTOR ALPHA;

AIR; AIR POUCH; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CALVARIA; CONTROLLED STUDY; DOWN REGULATION; DRUG ACTIVITY; FEMALE; GROWTH INHIBITION; HISTOPATHOLOGY; IMPLANTATION; INFLAMMATION; MOLECULAR BIOLOGY; MOUSE; NONHUMAN; OSTEOCLASTOGENESIS; OSTEOLYSIS; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; WESTERN BLOTTING;

ACID PHOSPHATASE; ANIMALS; BONE AND BONES; DOWN-REGULATION; ENZYME INHIBITORS; FEMALE; IMIDAZOLES; INFLAMMATION; ISOENZYMES; MATRIX METALLOPROTEINASE 9; MICE; MICE, INBRED BALB C; OSTEOCLASTS; OSTEOLYSIS; P38 MITOGEN-ACTIVATED PROTEIN KINASES; PYRIDINES; RNA, MESSENGER; TITANIUM; TUMOR NECROSIS FACTOR-ALPHA;

MURINAE; MUS;

EID: 84872192378     PISSN: 03603997     EISSN: 15732576     Source Type: Journal    
DOI: 10.1007/s10753-012-9500-3     Document Type: Article

References (30)

1. Mao, X., Pan, X., Peng, X., Cheng, T., and X. Zhang. 2010. Inhibition of titanium particle-induced inflammation by the proteasome inhibitor bortezomib in murine macrophage-like RAW 264.7 cells. Inflammation [Epub ahead of print].
2. Harris, W.H. 2001. Wear and periprosthetic osteolysis: The problem. Clinical Orthopaedics and Related Research 393: 66-70.
3. Pearl, J.I., T. Ma, A.R. Irani, Z. Huang, W.H. Robinson, R.L. Smith, and S.B. Goodman. 2011. Role of the Toll-like receptor pathway in the recognition of orthopedic implant wear-debris particles. Biomaterials 32: 5535-5542.
4. Geng, D.C., X.S. Zhu, H.Q. Mao, B. Meng, L. Chen, H.L. Yang, and Y.Z. Xu. 2011. Protection against titanium particle-induced osteoclastogenesis by cyclooxygenase-2 selective inhibitor. Journal of Biomedical Materials Research. Part A 99: 516-522.
5. Ingham, E., and J. Fisher. 2005. The role of macrophages in osteolysis of total joint replacement. Biomaterials 26: 1271-1286. (Pubitemid 39314501)
6. Purdue, P.E., P. Koulouvaris, H.G. Potter, B.J. Nestor, and T.P. Sculco. 2007. The cellular and molecular biology of periprosthetic osteolysis. Clinical Orthopaedics and Related Research 454: 251-261. (Pubitemid 46074927)
7. Abbas, S., J.C. Clohisy, and Y. Abu-Amer. 2003. Mitogenactivated protein (MAP) kinases mediate PMMA-induction of osteoclasts. Journal of Orthopaedic Research 21: 1041-1048. (Pubitemid 37322386)
8. Rakshit, D.S., K. Ly, T.K. Sengupta, B.J. Nestor, T.P. Sculco, L.B. Ivashkiv, and P.E. Purdue. 2006. Wear debris inhibition of anti-osteoclastogenic signaling by interleukin-6 and interferongamma. Mechanistic insights and implications for periprosthetic osteolysis. The Journal of Bone and Joint Surgery. American Volume 88: 788-799.
9. Yamanaka, Y., Y. Abu-Amer, R. Faccio, and J.C. Clohisy. 2006. Map kinase c-JUN N-terminal kinase mediates PMMA induction of osteoclasts. Journal of Orthopaedic Research 24: 1349-1357. (Pubitemid 44083250)
10. Lee, J.C., J.T. Laydon, P.C. McDonnell, T.F. Gallagher, S. Kumar, D. Green, D. McNulty, M.J. Blumenthal, J.R. Heys, S.W. Landvatter, et al. 1994. A protein kinase involved in the regulation of inflammatory cytokine biosynthesis. Nature 372: 739-746.
11. Ridley, S.H., S.J. Sarsfield, J.C. Lee, H.F. Bigg, T.E. Cawston, D.J. Taylor, D.L. DeWitt, and J. Saklatvala. 1997. Actions of IL-1 are selectively controlled by p38 mitogen-activated protein kinase: Regulation of prostaglandin H synthase-2, metalloproteinases, and IL-6 at different levels. The Journal of Immunology 158: 3165-3173. (Pubitemid 127484030)
12. Ren, W., S.Y. Yang, and P.H. Wooley. 2004. A novel murine model of orthopaedic wear-debris associated osteolysis. Scandinavian Journal of Rheumatology 33: 349-357. (Pubitemid 39421221)
13. Suzuki, M., K. Uetsuka, J. Shinozuka, H. Nakayama, and K. Doi. 1998. Changes in location and number of tartrate-resistant acid phosphatase (TRAP)-positive cells during the development of type II collagen-induced arthritis in DBA/1 J mice. Experimental Animals 47: 211-214. (Pubitemid 128437603)
14. Gallo, J., P. Kaminek, V. Ticha, P. Rihakova, and R. Ditmar. 2002. Particle disease. A comprehensive theory of periprosthetic osteolysis: A review. Biomedical Papers of the Medical Faculty of the University Palacky, Olomouc, Czech Republic 146: 21-28.
15. Dorr, L.D., Z. Wan, C. Shahrdar, L. Sirianni, M. Boutary, and A. Yun. 2005. Clinical performance of a Durasul highly cross-linked polyethylene acetabular liner for total hip arthroplasty at five years. The Journal of Bone and Joint Surgery. American Volume 87: 1816-1821. (Pubitemid 41061203)
16. Ren, W., X.H. Li, B.D. Chen, and P.H. Wooley. 2004. Erythromycin inhibits wear debris-induced osteoclastogenesis by modulation of murine macrophage NF-kappaB activity. Journal of Orthopaedic Research 22: 21-29. (Pubitemid 38035441)
17. von Knoch, F., A. Heckelei, C. Wedemeyer, G. Saxler, G. Hilken, F. Henschke, F. Loer, and M. von Knoch. 2005. The effect of simvastatin on polyethylene particle-induced osteolysis. Biomaterials 26: 3549-3555. (Pubitemid 40038149)
18. Goodman, S.B., and T. Ma. 2010. Cellular chemotaxis induced by wear particles from joint replacements. Biomaterials 31: 5045-5050.
19. Shimizu, S., N. Okuda, N. Kato, S.R. Rittling, A. Okawa, K. Shinomiya, T. Muneta, D.T. Denhardt, M. Noda, K. Tsuji, and Y. Asou. 2010. Osteopontin deficiency impairs wear debris-induced osteolysis via regulation of cytokine secretion from murine macrophages. Arthritis and Rheumatism 62: 1329-1337.
20. Vattakuzhi, Y., Abraham, S.M., Freidin, A., Clark, A.R., and N.J. Horwood. 2012. Dual specificity phosphatase 1 null mice exhibit spontaneous osteolytic disease and enhanced inflammatory osteolysis in experimental arthritis. Arthritis Rheum [Epub ahead of print].
21. Seo, S.W., D. Lee, H. Minematsu, A.D. Kim, M. Shin, S.K. Cho, D.W. Kim, J. Yang, and F.Y. Lee. 2010. Targeting extracellular signal-regulated kinase (ERK) signaling has therapeutic implications for inflammatory osteolysis. Bone 46: 695-702.
22. Wei, S., and G.P. Siegal. 2007. p38 MAPK as a potential therapeutic target for inflammatory osteolysis. Advances in Anatomic Pathology 14: 42-45. (Pubitemid 46052181)
23. Goodman, S.B., M. Trindade, T. Ma, M. Genovese, and R.L. Smith. 2005. Pharmacologic modulation of periprosthetic osteolysis. Clinical Orthopaedics and Related Research 430: 39-45. (Pubitemid 40096130)
24. Nawrocki, B., M. Polette, H. Burlet, P. Birembaut, and J.J. Adnet. 1999. Expression of gelatinase A and its activator MT1-MMP in the inflammatory periprosthetic response to polyethylene. Journal of Bone and Mineral Research 14: 288-294. (Pubitemid 29066255)
25. Ono, K., and J. Han. 2000. The p38 signal transduction pathway: Activation and function. Cellular Signalling 12: 1-13. (Pubitemid 30017963)
26. Welkoborsky, H.J. 2011. Current concepts of the pathogenesis of acquired middle ear cholesteatoma. Laryngo-Rhino-Otologie 90: 38-48.
27. Goodman, S.B., T. Ma, J. Spanogle, R. Chiu, K. Miyanishi, K. Oh, P. Plouhar, S. Wadsworth, and R.L. Smith. 2007. Effects of a p38 MAP kinase inhibitor on bone ingrowth and tissue differentiation in rabbit chambers. Journal of Biomedical Materials Research. Part A 81: 310-316. (Pubitemid 46668844)
28. Yasuda, S., H. Sugiura, H. Tanaka, S. Takigami, and K. Yamagata. 2011. p38 MAP kinase inhibitors as potential therapeutic drugs for neural diseases. Central Nervous System Agents in Medicinal Chemistry 11: 45-59.
29. Triantaphyllopoulos, K., L. Madden, I. Rioja, D. Essex, J. Buckton, R. Malhotra, K. Ray, M. Binks, and E.M. Paleolog. 2010. In vitro target validation and in vivo efficacy of p38 MAP kinase inhibition in established chronic collagen-induced arthritis model: a pre-clinical study. Clinical and Experimental Rheumatology 28: 176-185.
30. Hollenbach, E., M. Neumann, M. Vieth, A. Roessner, P. Malfertheiner, and M. Naumann. 2004. Inhibition of p38 MAP kinase- and RICK/NF-kappaB-signaling suppresses inflammatory bowel disease. The FASEB Journal 18: 1550-1552. (Pubitemid 39561629)